Clinical Trial Update: A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating ARQ 197 in adult patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ARQ 197 (tivantinib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Cancer | Phase 1 | Status: COMPLETED